Clinical Trial Update: Proof of Concept Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Severe Eosinophilic Asthma [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-concept study evaluating Etokimab (ANB020) in adults with severe eosinophilic asthma has completed, with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• Etokimab

Snippet

Sponsor: AnaptysBio, Inc. | Conditions: Eosinophilic Asthma | Phase 2 | Status: COMPLETED | Results posted: 2023-08-16